Season 5

CONTENT AND LEARNING OBJECTIVES:

There has been much controversy surrounding the recent surge in demand and availability of the weight loss drug, Semaglutide, which is sold under the brand names Wegovy, Ozempic and Rybelsus.

The medication, originally developed for the treatment of type 2 diabetes, has recently been approved for use in the UK for weight management. Semaglutide is a GLP-1 receptor agonist, and has been suggested to be the most important breakthrough in obesity treatment to date, but what does the evidence say?

In this Journal Club session, we’ll discuss a recently published clinical trial paper investigating the results from 2 years follow-up of GLP-1 receptor agonist, semaglutide.

This session covers:

• What GLP-1 is and its role in physiology
• The effects of GLP-1 receptor agonist on weight change and food intake
• Evidence for change in relationship with food, food choice and cravings
• Other effects of GLP-1 on the body
• How to evaluate data from a clinical trial and appreciate limitations

Expert speaker

Professor Giles Yeo
Professor of Molecular Neuroendocrinology, MRC Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge

@gilesyeo

Giles Yeo is a Professor of Molecular Neuroendocrinology and programme leader at the MRC Metabolic Diseases Unit in Cambridge and his research currently focuses on the influence of genes on feeding behaviour & body-weight. He is a fellow of Wolfson College, and Honorary President of the British Dietetic Association.

Paper reference

Wharton, S, Batterham, RL, Bhatta, M, et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring). 2023; 31(3): 703-715. doi: https://doi.org/10.1002/oby.23673

About Journal Club Chair, Dr Pippa Gibson RNutr PhD

@drpippagibson

Each Journal Club session is chaired by Dr Pippa Gibson. Pippa gained her BSc and PhD from the University of Surrey, where she studied the role of vitamin D on the progression of paediatric liver disease. Pippa moved to King’s College London to complete a postdoc on interesterified fats on cardiovascular health before moving into the gastrointestinal health team investigating the role of dietary compounds on constipation and functional bloating. Now, Pippa is Head of Nutrition for a contract catering company and primarily works in nutrition education in schools, promoting health messages across all ages, and regularly contributes to the MyNutriWeb blogs.

CPD CERTIFICATE & LEARNING MATERIALS

Once you have viewed a full recorded session the mynutriweb team will review and arrange to send you your certificate via email from hello@mynutriweb.com within two weeks of viewing the session.